|
Video: What is a Stock Split?
|
|
TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, Co. has received approval from the U.S. Food and Drug Administration for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Co. also evaluates products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. According to our TG Therapeutics stock split history records, TG Therapeutics has had 2 splits. | |
|
TG Therapeutics (TGTX) has 2 splits in our TG Therapeutics stock split history database. The first split for TGTX took place on July 14, 2011. This was a 1 for 50 reverse split, meaning for each 50 shares of TGTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split. TGTX's second split took place on July 19, 2011.
When a company such as TG Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TG Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TG Therapeutics shares, starting with a $10,000 purchase of TGTX, presented on a split-history-adjusted basis factoring in the complete TG Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$6.90 |
|
End price/share: |
$15.57 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
125.65% |
|
Average Annual Total Return: |
8.48% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$22,563.16 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
07/14/2011 | 1 for 50 | 07/19/2011 | 1 for 1 |
|
|